Saturday, 31 October 2026European Markets

HOFSETH BIOCARE Stock Over 22% Up In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of HOFSETH BIOCARE (Oslo Børs Benchmark Index_GI: HBC.OL) rose by a staggering 22.4% in 10 sessions from kr2.5 to kr3.06 at 13:38 EST on Thursday, following the last session's upward trend. Oslo Børs Benchmark Index_GI is jumping 0.54% to kr1,249.22, after two consecutive sessions in a row of gains.

HOFSETH BIOCARE's last close was kr2.88, 46.86% below its 52-week high of kr5.42.

About HOFSETH BIOCARE

Hofseth BioCare ASA operates as a consumer and pet health ingredient supplier in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for supporting healthy cholesterol and cardiovascular function; ProGo, a salmon protein hydrolysate powder for treatment of irondeficiency anaemia, irritable bowel syndrome (IBS) and sarcopenia; CalGo, a marine calcium powder produced to support cartilage function, joint health, and bone strength; CollaGo, an hair, skin, and nails health treatment and antioxidant; and PetGo, a non-soluble protein. The company distributes its products through distributors, agents, and its own sales force. Hofseth BioCare ASA was founded in 2000 and is headquartered in Ålesund, Norway.

Earnings Per Share

As for profitability, HOFSETH BIOCARE has a trailing twelve months EPS of kr-0.31.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -94.78%.

Volume

Today's last reported volume for HOFSETH BIOCARE is 184259 which is 31.16% below its average volume of 127327.

Moving Average

HOFSETH BIOCARE's value is higher than its 50-day moving average of kr2.89 and below its 200-day moving average of kr3.27.

More news about HOFSETH BIOCARE (HBC.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com